Nano Dimension, a 3D printing electronics company, has revealed plans to launch a subsidiary focused on solutions for end-stage renal disease, a condition that leads to kidney failure.
The Israel-based company will create a platform for the 3D bio-printing of cells and connective tissues to form biological structures that function as human kidneys.
In a statement
released yesterday, February 13, Amit Dror, CEO of Nano Dimension, said: "We believe that our high-end 3D printing capabilities, together with our expertise in nano-chemistry and advanced materials, provide significant added value to the promising field of bio-printing."
He added that the company looks forward to bringing its know-how and intellectual property in multi-material 3D printing and integrating it into the emerging world of 3D bio-printing.
Nano Dimension will advance its initiative through the new subsidiary, which will seek separate funding and be distinct from the company’s activity in the field of printed electronics.
Nano Dimension, 3D printing, bio-printing, kidney, end-stage renal disease, intellectual property